Sign In
Buy EDSA
$5.11
-0.140 (-2.67%)
At Close: Jul 31, 2026
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
07:30am, Thursday, 03'rd Jun 2021
TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the co
Edesa Biotech to Join Panel Discussion at Industry Event
08:00am, Friday, 28'th May 2021
TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
08:00am, Friday, 14'th May 2021
TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial re
Edesa Biotech Reaches Enrollment Milestone in COVID Study
08:10am, Monday, 15'th Mar 2021
TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it h
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
07:30am, Tuesday, 09'th Mar 2021
TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it ha
Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares
04:10pm, Tuesday, 02'nd Mar 2021
TORONTO, ON / ACCESSWIRE / March 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closin
EDSA Stock Price Increases Over 77% Pre-Market: Why It Happened
08:50am, Tuesday, 26'th Jan 2021
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 77% pre-market. This is why it happened.
Edesa Biotech Expands COVID-19 Clinical Study to Colombia
07:30am, Monday, 11'th Jan 2021
TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to e
Edesa Biotech Issues Letter to Shareholders
08:00am, Wednesday, 30'th Dec 2020
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijh
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
11:45am, Wednesday, 12'th Aug 2020
TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc.
Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
11:45am, Thursday, 30'th Jul 2020
TORONTO, ON / ACCESSWIRE / July 30, 2020 / Edesa Biotech, Inc.
Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study
12:15pm, Monday, 15'th Jun 2020
TORONTO, ON / ACCESSWIRE / June 15, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical stud
EDSA: Interim Analysis of Phase 2b Trial of EB01 in second half of 2020…
11:20am, Wednesday, 27'th May 2020
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Update on Phase 2b Trial of EB01 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a Phase 2b clinical trial
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Be Considered Quite Risky
10:47am, Tuesday, 19'th May 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results
12:00pm, Friday, 15'th May 2020
TORONTO, ON / ACCESSWIRE / May 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended March 31, 2
